Tenosynovial Giant Cell Tumors Market to Expand Significantly by 2034, States DelveInsight Report

DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tenosynovial Giant Cell Tumors Market Forecast
https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Tenosynovial Giant Cell Tumors Market Report:
• The Tenosynovial Giant Cell Tumors market size was valued approximately USD 300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, Merck, a global leader in science and technology, announced the upcoming presentation of new oncology data spanning over 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 to June 4 in Chicago. Among the highlights is Phase 3 MANEUVER trial data for pimicotinib, a potential best-in-class therapy for the rare tumor TGCT. The presentations will feature results from both company-led and investigator-initiated studies, underscoring Merck's commitment to developing innovative therapies targeting some of the most difficult-to-treat cancers.
• In April 2025, SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company focused on developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab. This designation applies to TGCT patients who are not candidates for surgery or are unlikely to benefit from it. Emactuzumab, a promising CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody, is currently under investigation in the TANGENT study-a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 registrational trial.
• In March 2025, Tenosynovial giant cell tumor (TGCT), also referred to as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is mainly managed through surgical removal. In cases of localized TGCT, treatment usually involves excising the tumor nodule. However, diffuse-type TGCT (DTGCT) typically affects larger areas and major joints, making treatment more challenging. Management strategies for DTGCT may include total synovectomy, joint replacement, or, in very rare instances, amputation. DTGCT may include complete synovectomy, joint replacement, or, in very rare instances, amputation.
• In February 2025, Ono Pharmaceutical Co., Ltd. (Headquartered in Osaka, Japan; President: Toichi Takino) has announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZATM (vimseltinib), a kinase inhibitor, for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) where surgical removal could lead to significant functional impairment or serious complications. ROMVIMZA, developed by Deciphera Pharmaceuticals, Inc.-a wholly owned subsidiary of Ono-had previously received Fast Track designation and Priority Review from the FDA.
• In April 2024, SynOx Therapeutics secured USD 75 million in Series B funding. The raised capital will be allocated towards obtaining registrational Phase 3 clinical data and chemistry, manufacturing, and controls (CMC) data for emactuzumab, a monoclonal antibody (mAb) inhibiting CSF-1(R), intended for treating tenosynovial giant cell tumor (TGCT).
• In the seven major markets (7MM), localized tenosynovial giant cell tumor (TGCT) comprised approximately 80% of all TGCT cases in 2023.
• In the seven major markets (7MM), localized tenosynovial giant cell tumor (TGCT) was predominantly located in the digits, representing approximately 75% of all cases in 2023.
• Giant cell tumors can manifest in various joints such as the knee, ankle, and hip, depending on whether they are localized or diffuse. DelveInsight's estimates suggest that for diffuse TGCT, the highest tumor localization was observed in the knee, with approximately 30,000 cases in the United States in 2023.
• Despite the introduction of novel CSF1R inhibitors, the market size of off-label systemic therapies (such as imatinib, sunitinib, and others) is anticipated to exhibit stagnant growth in the forecast period. This is attributed to the rising prevalence of cases in the seven major markets (7MM).
• Key Tenosynovial Giant Cell Tumors Companies: Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others
• Key Tenosynovial Giant Cell Tumors Therapies: Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others
• The Tenosynovial Giant Cell Tumors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tenosynovial Giant Cell Tumors pipeline products will significantly revolutionize the Tenosynovial Giant Cell Tumors market dynamics.

Tenosynovial Giant Cell Tumors Overview
Tenosynovial Giant Cell Tumors (TGCT) are rare, typically benign tumors that occur in the joint lining, tendon sheaths, or bursae. They can cause pain, swelling, and restricted movement in the affected area, commonly impacting the knees, hips, or fingers. TGCT is divided into localized and diffuse types, with the latter being more aggressive and likely to recur.

Get a Free sample for the Tenosynovial Giant Cell Tumors Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Tenosynovial Giant Cell Tumors Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Tenosynovial Giant Cell Tumors Epidemiology Segmentation:
The Tenosynovial Giant Cell Tumors market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Tenosynovial Giant Cell Tumors
• Prevalent Cases of Tenosynovial Giant Cell Tumors by severity
• Gender-specific Prevalence of Tenosynovial Giant Cell Tumors
• Diagnosed Cases of Episodic and Chronic Tenosynovial Giant Cell Tumors

Download the report to understand which factors are driving Tenosynovial Giant Cell Tumors epidemiology trends @ Tenosynovial Giant Cell Tumors Epidemiology Forecast
https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Tenosynovial Giant Cell Tumors Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tenosynovial Giant Cell Tumors market or expected to get launched during the study period. The analysis covers Tenosynovial Giant Cell Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Tenosynovial Giant Cell Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Tenosynovial Giant Cell Tumors Therapies and Key Companies
• Pexidartinib: Daiichi Sankyo Co., Ltd.
• vimseltinib: Deciphera Pharmaceuticals
• Pimicotinib(ABSK021): Abbisko Therapeutics
• AMB-05X: AmMax Bio, Inc.
• Emactuzumab: SynOx Therapeutics Limited
• Pimicotinib(ABSK021): Abbisko Therapeutics
• FPA008: Five Prime Therapeutics
• MCS110: Novartis

Discover more about therapies set to grab major Tenosynovial Giant Cell Tumors market share @ Tenosynovial Giant Cell Tumors Treatment Landscape
https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Tenosynovial Giant Cell Tumors Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Tenosynovial Giant Cell Tumors Companies: Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others
• Key Tenosynovial Giant Cell Tumors Therapies: Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others
• Tenosynovial Giant Cell Tumors Therapeutic Assessment: Tenosynovial Giant Cell Tumors current marketed and Tenosynovial Giant Cell Tumors emerging therapies
• Tenosynovial Giant Cell Tumors Market Dynamics: Tenosynovial Giant Cell Tumors market drivers and Tenosynovial Giant Cell Tumors market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Tenosynovial Giant Cell Tumors Unmet Needs, KOL's views, Analyst's views, Tenosynovial Giant Cell Tumors Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.